Cervical Dysplasia
65
9
10
37
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.2%
4 terminated out of 65 trials
90.2%
+3.7% vs benchmark
6%
4 trials in Phase 3/4
14%
5 of 37 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 37 completed trials
Clinical Trials (65)
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Large Loop Excision of the Transformation Zone (LLETZ) With vs Without IntraOperative Application of Lugol's Iodine
Self-sampling for Non-attenders to Cervical Cancer Screening
Effectiveness of a Vaginal Gel on CIN1/2 Regression and HPV Clearance.
Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring
iMproving thE DIagnostics And Treatment Of ceRvical Precancer
The Mother-Daughter Project: Merck-4
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers
Effect of a Childcare Resource on Cervical Cancer Prevention
Reshaping Postpartum Follow-up
What is the Optimal Training Model for Cervical Awareness?
Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.
Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments
Long Term Follow-up of HPV Vaccine in HIV (CTN 236)
Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC)
Interferon Alpha Therapy for Cervical CINI and HPV Infection
The Use of the LuViva Advanced Cervical Scan to Identify Women at High-Risk for Cervical Neoplasia
Sexual Function and Quality of Life After LEEP: a Prospective Multi-Center Study
Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia